WeightWatchers pivots to clinical weight loss as GLP-1 drugs reshape industry

WeightWatchers pivots to clinical weight loss as GLP-1 drugs reshape industry

Mitchell Wilson
Mitchell Wilson
2 Min.
Scatter plot on a white background showing the correlation between weight loss and different types of placebo pills, with the title "weight loss vs placebo pills" above the data points.

WeightWatchers pivots to clinical weight loss as GLP-1 drugs reshape industry

WW International, formerly known as WeightWatchers, has reported its latest financial results while outlining a major shift in strategy. The company is now focusing on clinical weight management, including partnerships with GLP-1 medication providers, as traditional diet programmes lose appeal. Leadership also highlighted strong progress in reducing debt and rebuilding the business after emerging from Chapter 11.

The company ended Q4 with $160 million in cash and cash equivalents. Total revenue for the quarter reached $163 million, a 12% drop compared to the same period last year. However, clinical revenue grew by 32%, offsetting a 17% decline in behavioural revenue.

Monthly subscription revenue per subscriber rose by 8% year-over-year to $18.73. This increase was driven by higher-value clinical services and uptake of the Core+ programme. Felicia DellaFortuna, CFO, reported 130,000 clinical subscribers at the end of the period. The company expects this number to reach around 200,000 by Q1 2026—nearly double the current figure.

Tara Comonte, President and CEO, confirmed that WW has cut its legacy debt by over 70% since exiting Chapter 11. She also noted a permanent industry shift due to GLP-1 medications, forcing the company to adapt. Management projects 2026 revenue between $620 million and $635 million, with adjusted EBITDA in the range of $105 million to $115 million.

Despite growth in clinical services, the company faces challenges. A projected $50 million headwind in subscription revenue for 2026 stems from declining behavioural subscribers. WW has repositioned itself with investments in clinical partnerships and technology, moving away from standalone behavioural programmes.

WW International is now prioritising clinical weight management solutions, including GLP-1 integration, to counter declining demand for traditional diet plans. With debt reduced and leadership restructured, the company aims to stabilise revenue through higher-value offerings. The shift reflects broader industry changes as medication-based weight loss gains prominence.

Neueste Nachrichten